CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($) $ in Thousands		Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Beginning balance at Dec. 31, 2020		$ 35	$ 320,280	$ (347,352)	$ (27,037)
Beginning balance (in shares) at Dec. 31, 2020	[1]	34,765,280
Issuance of common stock, net of issuance cost		$ 9	37,616		37,625
Issuance of common stock, net of issuance cost (in shares)	[1]	8,749,999
Issuance of common stock under the Sales Agreement, net		$ 2	8,573		8,575
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	1,867,552
Share-based compensation related to stock options			510		510
Share-based compensation related to restricted stock awards			306		306
Net loss for the period				(5,475)	(5,475)
Ending balance at Mar. 31, 2021		$ 46	367,285	(352,827)	14,504
Ending balance (in shares) at Mar. 31, 2021	[1]	45,382,831
Beginning balance at Dec. 31, 2021		$ 46	368,852	(374,934)	(6,036)
Beginning balance (in shares) at Dec. 31, 2021	[1]	45,556,647
Share-based compensation related to stock options			149		149
Share-based compensation related to restricted stock awards			687		687
Share-based compensation related to restricted stock awards (in shares)	[1]	759,482
Net loss for the period				(2,286)	(2,286)
Ending balance at Mar. 31, 2022		$ 46	$ 369,688	$ (377,220)	$ (7,486)
Ending balance (in shares) at Mar. 31, 2022	[1]	46,316,129

[1] Common stock, $0.001 par value; Authorized – as of March 31, 2022 and 2021 - 120,000,000 shares.